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Abstract
Objective—Investigate the impact of probiotic Bifidobacterium longum ssp infantis on the fecal 
microbiota and plasma cytokines in neonates with congenital heart disease.
Study design—Sixteen infants with congenital heart disease were randomly assigned to receive 
either B. infantis (4.2 × 109 cfu twice daily) or placebo for 8 weeks. Stool specimens from enrolled 
infants and from six term infants without heart disease were analyzed for microbial composition. 
Plasma cytokines were analyzed weekly in the infants with heart disease.
Results—Healthy control infants had increased total bacteria, total Bacteroidetes, and total 
bifidobacteria compared to the infants with heart disease, but there were no significant differences 
between the placebo and probiotic groups. Plasma IL10, IFNγ, and IL1β levels were transiently 
higher in the probiotic group.
Conclusions—Congenital heart disease in infants is associated with dysbiosis. Probiotic B. 
infantis did not significantly alter the fecal microbiota. Alterations in plasma cytokines were 
inconsistent.
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Introduction
Necrotizing enterocolitis (NEC) is predominantly a disease of premature infants. Among 
term infants, the prevalence of NEC has been estimated at 1 in 20,000 live births.1 
Congenital heart disease (CHD) is one of the most consistent risk factors for NEC in term 
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infants. In two case series about one third of term infants with NEC had CHD.1, 2 Among 
term infants with CHD requiring surgery in the neonatal period, the incidence of NEC has 
been reported to be 3–7%, which is similar to the incidence among premature infants.3, 4 
Mortality rates among infants with CCHD who develop NEC, however, may be even greater 
than in premature infants5, 6 with one study reporting mortality as high as 71%.7
In premature infants primary risk factors for NEC include immaturity, enteral feeding, and 
atypical development of the intestinal microbiota (dysbiosis).8 In premature infants the most 
promising interventions in prevention of NEC include human milk9 and probiotics.10 
Probiotics have been shown to decrease gene expression of pro-inflammatory cytokines11 
and to alter the intestinal microbiota.12 Whether the pathophysiology of NEC in term infants 
with CHD is similar to that in premature infants is unknown.
We performed a pilot study of probiotic administration to term infants scheduled for cardiac 
surgery within the first weeks of life. Our hypotheses were that term infants with CHD 
would have a markedly different intestinal microbiota than healthy term infants and that 
administration of probiotic bifidobacteria to term infants with CHD would alter the intestinal 
microbiota and the levels of plasma cytokines.
Patients and Methods
This trial was performed at UC Davis Children’s Hospital in Sacramento, California from 
Aug 2009 to Dec 2010 following approval from the Institutional Review Board and 
registration at clinicaltrials.gov (NCT01018472). Eligible infants included those with 
gestational age at least 34 weeks, congenital heart disease requiring repair in the neonatal 
period, and absence of congenital gastrointestinal anomalies. Following informed consent 
from the parents, infants were randomly assigned by the UC Davis Investigational Pharmacy 
to receive either 4.2 × 109 colony forming units of Bifidobacterium longum ssp infantis 
ATCC 15697 or a placebo twice daily for eight weeks or until death or discharge if sooner.
The probiotic strain was chosen based on its genetic capacity to digest human milk 
oligosaccharides, an advantage in colonizing the neonatal intestinal tract.13 To avoid the 
drawbacks of over-the-counter probiotic products (e.g. inconsistent composition and 
viability)14 the probiotic strain was grown by a food-grade commercial facility (Culture 
Systems, Inc., Mishawaka, IN) and stored at −80 degrees C. Purity and number of viable 
bacteria was confirmed every six months by culture techniques. The placebo was a dilute 
formulation of Pregestimil powder (Mead Johnson) without significant caloric value. The 
investigators, clinical research coordinator, caregivers and parents were blinded as to group 
of assignment.
Feces were obtained from a soiled diaper prior to the first dose of the study product and then 
weekly thereafter when possible. Fecal samples were refrigerated overnight, transported on 
dry ice and stored at −80 degrees C. One ml of blood was obtained at enrollment and then 
weekly for 5 weeks when possible. The blood was centrifuged at 3000 rpm for 15 minutes 
and the plasma frozen at −80 degrees C.
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The healthy comparison group consisted of 6 term breast-fed infants. None had congenital 
heart disease, required hospitalization or were treated with antibiotics or probiotics during 
the study period. Stool samples were obtained from a soiled diaper by the parents at regular 
intervals and kept on ice until transport within 12 hours and storage at −80 degrees C.
DNA extraction
Bacterial genomic DNA was extracted from stool samples as previously described with a 
few modifications.15 Briefly, frozen stool was thawed and centrifuged (8,000 × g for 5 min 
at room temperature). The fecal pellet was rinsed twice with PBS then resuspended in 200 μl 
lysis buffer (2 mM EDTA, 1.2 % TritonX-100, 20 mM Tris-HCl, pH 8.0) with freshly added 
40 mg/ml lysozyme. The solution was incubated at 37°C for 30 min. Buffer ASL from 
QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) was added to equal 2.0 ml, vortexed 
until thoroughly mixed, and then homogenized by bead-beating in a FastPrep-24 Instrument 
(MP Biomedicals, Solon, OH) for 2 min at 6.5 m/sec. The homogenate was incubated for 5 
min at 95°C, vortexed, and centrifuged at 13,000 × g for 1 min to pellet stool particles. DNA 
in the supernatant was purified with the Qiagen Stool Mini Kit.
qPCR
SYBR green and TaqMan quantitative real time PCR (qPCR) assays were performed on a 
7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA) with primers 
specific for universal eubacteria and bifidobacteria. Universal eubacteria SYBR green assays 
contained 10 μl of 2x Takara Perfect Real Time master mix (Clontech Laboratories, 
Mountain View, CA), 6 μl water, 400 nM of forward and reverse primers (all primers listed 
in the supplementary information Table A), and 2 μl diluted 1:100 genomic DNA with 
cycling conditions as previously described.16 Bifidobacteria TaqMan qPCR assays 
contained 12.5 μl 2x TaqMan Universal PCR master mix (Applied Biosystems), 300 nM of 
forward and reverse primers, 150 nM TaqMan probe, 3.75 μl water, and 2.5 μl diluted 1:100 
genomic DNA17 with cycling conditions as previously described.16 All reactions were 
carried out in triplicate with a nontemplate control.
TRFLP analysis of the fecal microbiota
PCR amplification was performed in 50-μL reactions containing 1–5 ng of DNA template, 
25 μL 2X Promega GoTaq Green Master Mix (Promega, Madison, WI), 1 mM MgCl2, and 2 
pmol of each primer). 18,19 Each PCR was performed in triplicate and the products 
combined prior to purification. The PCR conditions were an initial denaturation at 95°C for 
2 min, followed by 30 cycles of denaturation at 95°C for 30 sec, annealing at 50°C for 30 
sec, and extension at 72°C for 2 min, with a final extension at 72°C for 5 min.
A focused TRFLP of non-clostridial Firmicutes was performed as described.20 PCR 
conditions consisted of an initial denaturation at 95°C for 5 min, followed by 30 cycles of 
denaturation at 95°C for 45 sec, annealing at 66°C for 30 sec, and extension at 72°C for 45 
sec, with a final extension at 72°C for 5 min.
PCR products were analyzed by electrophoresis and purified using the QIAquick PCR 
Purification Kit (Qiagen, Valencia, CA). All 16S-TRFLP amplicons were digested using the 
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enzymes AluI, MspI, HaeIII, and HhaI. Focused TRFLP amplicons were digested using the 
enzymes MseI, Hpy188I, and Hpy188III. Next, 1.5 μl of the digestion mixture was used for 
fragment analysis and traces were visualized with the program Peak Scanner v1.0 (Applied 
Biosystems). Peak filtration and clustering analyses were performed with R software, using 
published program scripts and analysis protocols.21
Taxonomic assignments of operational taxonomic units were based on comparison to an in 
silico digest database generated by the virtual digest tool from MiCA22 of good-quality 16S 
rRNA gene sequences compiled by the Ribosomal Database Project Release.23, 24
Cytokine analysis
Plasma cytokines were quantified using high sensitivity human multiplexing bead 
immunoassays (Millipore Corporation, St. Charles, MO) based on a sandwich immunoassay 
utilizing the Luminex fluorescent-bead-based technology following established protocols25. 
Briefly, 50 ul of plasma were incubated with antibody-coupled beads. After a series of 
washes, a biotinylated detection antibody was added followed by streptavidin-phycoerythrin. 
The bead sets were analyzed using a flow-based Luminex™ 100 suspension array system 
(Bio-Plex 200; Bio-Rad Laboratories, Inc.). Unknown sample cytokine concentrations were 
calculated by Bio-Plex Manager software using a standard curve derived from the known 
reference cytokine concentrations. A five-parameter model was used to calculate final 
concentrations.
Statistical analysis
Using QIIME software, multidimensional summary measures of the microbial composition 
of the fecal samples analyzed by 16S-TRFLP were derived and visualized in a reduced 
number of dimensions via a 3-dimensional principal coordinate analysis (PCoA) plot.26 
Shannon diversity indices were calculated from the TRFLP data.
qPCR and cytokine data were log transformed and analyzed in STATA (version 9, 2007) 
using repeated measures ANOVA. For data that did not approximate a normal distribution 
after log transformation, the non-parametric Kruskal-Wallis test was used at specific time 
points. For the baseline and combined qPCR data and the combined Shannon diversity 
indices standard one-way ANOVA with Scheffe’s test for differences between groups was 
used. For the qPCR data, readings of zero were presumed to represent 1 × 104, the lower 
limit of detection. Given that this pilot study was designed to generate hypotheses rather 
than test them we report p values < 0.1 as being of interest for possible future testing.
Results
Sixteen infants with congenital heart disease were enrolled in the study. Two of the infants 
were removed from the study prior to receiving the study product, one because of transfer to 
another facility (placebo group) and one at the request of the parents (probiotic group). 
Baseline specimens, demographic and clinical data were included for both on an intention-
to-treat basis. A summary of patient details is provided in Table 1 with patient-specific 
details in the supplementary information (Table B). The groups were similar except for age 
at enrollment.
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TRFLP and qPCR are complementary techniques with the former providing an overview of 
all identifiable bacteria and the latter providing more precise quantification of total bacteria 
and specific taxa. Figure 1 presents the mean percentages of bacterial phyla by TRFLP for 
each group over time. Bacteroidetes were more common in the healthy control infants than 
the CHD infants at baseline, weeks 1–6, and weeks 7 and greater (Kruskal-Wallis p=0.036, 
068, and 0.041). Actinobacteria showed the same pattern (Kruskal-Wallis p=0.017, 0.023, 
and 0.035 at the same time points). Firmicutes were more common in infants with CHD but 
only at the middle time points (weeks 1–6, Kruskal-Wallis p=0.052). No significant 
differences were noted between the placebo and probiotic groups. The TRFLP data for each 
individual infant at the class/order level are presented in the supplementary information 
(Figure A). The phylum Firmicutes includes the Gram-positive classes Clostridia, Bacilli, 
and Negativicutes. To characterize the non-clostridial Firmicutes, focused TFRLP analysis 
was performed for each specimen for three of the control infants and fourteen of the infants 
with heart disease. All groups showed a predominance of streptococci with no detectable 
lactobacilli. A trend towards decreased enterococci in the healthy controls did not reach 
statistical significance (supplementary information: group comparison in Figure B with 
individual analyses in Table C. Figure 2 is the principal coordinate analysis of the TRFLP 
data. Each circle represents one specimen with increased distance between circles reflective 
of greater differences in microbial composition. The Shannon diversity indices [mean(SD)] 
were 2.3(0.22) for the infants without CHD, 2.1(0.40) for the probiotic group, and 
1.92(0.51) for the placebo (ANOVA p=0.24).
Figure 3 presents the mean qPCR data for total bacteria, total Enterobacteriaceae, and total 
bifidobacteria for each group over time. The healthy control infants without CHD had 
greater total bacteria, total Enterobacteriaceae, and total bifidobacteria at baseline and in the 
combined non-baseline specimens (Figure 4). The individual q-PCR analyses for each infant 
are presented in the supplementary information (Figure C). Primers specific for B. longum 
were used to assess what proportion of fecal bifidobacteria are the same species as the 
ingested probiotic. Among the infants receiving the probiotic, 93% of the bifidobacteria 
identified were B. longum, whereas among the infants receiving placebo, 72% were B. 
longum. Whether this represents cross-contamination as has been demonstrated in other 
probiotic studies27 is unclear. The mean percentage of bifidobacteria identified as B. longum 
from three of the control infants (B, C, and D) were 43%, 58%, and 0%.
Figure 4 presents levels of four cytokines in the CHD infants. Differences between groups 
over time were significant for IFNγ (p=0.007) and IL1β (p=0.04), with the following 
differences at individual weeks: IFNγ week 1 (p=0.08), IL1β week 3 (p=0.06), and IL10 
week 2 (p=0.06). No trends were noted for TNFα or IL8 (data not shown).
Discussion
In the premature infant, NEC is common and devastating. The pathophysiology of this 
disease is incompletely understood. Major risk factors in the premature infant include degree 
of prematurity, formula feeding, and dysbiosis.8 Other possible risk factors include red 
blood cell transfusion28 and maternal smoking.29 Prematurity remains the most prominent 
predictor of NEC risk and is likely related to immaturity of multiple aspects of gastro-
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intestinal mucosal immunity (including barrier integrity, signaling, pro-inflammatory 
responses, Paneth cell function, secretion of antimicrobial molecules, autophagy, and 
apoptosis).30–32 Four strands of evidence link dysbiosis and NEC in the premature infant. 
First, prolonged antibiotic exposure is associated with NEC.33 Second, increased numbers of 
Gram-negative Enterobactericeae dominate the feces of NEC patients.34, 35 Third, multiple 
clinical trials demonstrate decreased risk of NEC in premature infants receiving probiotics.36 
Fourth, acid suppression changes the fecal microbiota and increases risk of developing NEC 
in premature infants.37, 38
In the term infant, NEC is relatively rare. Among this population, the association between 
CHD and NEC is well established, however given the relatively small number of cases of 
NEC in term infants with heart disease at any single institution, the pathophysiology of this 
form of NEC is unexplored.39 In particular it is unknown whether formula feeding, 
dysbiosis, transfusion, maternal smoking, dysfunction of mucosal immunity, or alterations in 
oxygenation or perfusion of the intestine are significant risk factors in this population.
The purpose of this pilot study was to generate preliminary data to begin to address two 
hypotheses: that infants with CHD would demonstrate significant intestinal dysbiosis and 
that probiotic B. infantis would partially “normalize” the microbiota (i.e. shift the 
composition towards that of the healthy infant). This study supports the first hypothesis in 
that infants with CHD develop an altered fecal microbiota most marked by decreased total 
bacteria, decreased Actinobacteria (predominantly bifidobacteria), decreased Bacteroidetes, 
decreased Enterobactericeae, and increased Firmicutes (predominantly enterococci). 
However, no significant differences in the composition of the fecal microbiota were noted 
between the two groups of infants with heart disease, suggesting against our second 
hypothesis. The lack of a significant increase in fecal bifidobacteria with probiotic treatment 
in this population differs from observations with this organism in hospitalized premature 
infants (manuscript submitted). It is possible that other influences on the intestinal 
microbiota including timing and type of enteral feeding, antibiotic treatment, inhibition of 
acid suppression, and hypoxia and/or ischemia play such a large role in shaping the 
microbiota that the influence of the probiotic is minimal.
Several Gram-negative Enterobacteriaceae have been shown to trigger an inflammatory 
response in the intestinal mucosa and then out-compete the commensal organisms in this 
pro-inflammatory environment.40 One possible mechanism for the observed anti-
inflammatory effects of probiotics is the displacement of this pro-inflammatory population. 
We included analysis of plasma cytokines to explore the hypothesis that alterations in the 
microbiota were associated with changes in key cytokines implicated in NEC. As we were 
unable to observe significant changes in the microbiota related to the probiotic 
administration, this hypothesis remains untested in this population.
Pilot studies provide preliminary data to determine sample size and/or justify larger 
definitive studies. NEC occurs at a younger age in term infants than premature infants 
suggesting that a beneficial effect of probiotics would need to manifest quickly. Based on 
changes seen after one week of probiotic or placebo in this study, sample size calculations 
for definitive studies of several possible outcomes are summarized in Table 2. A clinical 
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trial of probiotics in term infants with congenital heart disease to decrease risk of NEC 
would require several hundred infants in each arm, however a moderate sized trial to assess 
short term increases in fecal bifidobacteria or beneficial changes in cytokines appears 
justifiable.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mean TRFLP percentages of bacterial phyla by group over time. Ba=baseline specimens.
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Figure 2. 
Principle coordinate analysis of all TRFLP data (open circles = CHD + B. infantis, black 
circles = CHD + placebo, open squares = controls without CHD).
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Figure 3. 
Mean numbers of total bacteria (white bars), Enterobacteriaceae (light gray bars), and 
bifidobacteria (dark gray bars) by qPCR for each group over time. The Y axis is a 
logarithmic scale and represents copies of specific 16S rRNA gene sequences (rDNA) per g 
stool.
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Figure 4. 
Box plots of qPCR data for each group at baseline and all subsequent time periods 
combined. The Y axis is log transformed copies of the 16S rRNA gene per g stool. Total 
bacteria (baseline ANOVA p=0.03 [Scheffe p=0.07 probiotic v control and p=0.06 placebo 
v control]; weeks 1–11 ANOVA p=0.001 [Scheffe p=0.002 placebo v control]). Total 
Enterobacteriaceae (baseline ANOVA p=0.003 [Scheffe p=0.006 probiotic v control and 
p=0.01 placebo v control]; weeks 1–11 ANOVA p=0.07 [Scheffe p=0.07 probiotic v 
control]). Total bifidobacteria (baseline ANOVA p=0.02 [Scheffe p=0.02 probiotic v control 
and p=0.05 placebo v control]; weeks 1–11 ANOVA p=0.008 [Scheffe p=0.04 probiotic v 
control and p=0.01 placebo v control]).
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Figure 5. 
Box plots of plasma cytokines for the two groups of infants with CHD for each study week. 
White boxes=probiotic group, gray boxes=placebo group. Y axes are pg/mL.
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Table 1
Patient data summary.
Probiotic (n=8) Placebo (n=8)
Birth weight gm, mean (SD) 3024 (484) 2889 (533)
Gestational age wks, mean (SD) 38.4 (1.2) 37.4 (2.4)
Delivery (% C-section) 37.5 50
Gender (% male) 37.5 50
1 min Apgar, median (quartiles) 7 (2,8) 8 (7,8)
5 min Apgar, median (quartiles) 8 (8,9) 8 (7,9)
Feeding (% receiving some EBM) 87.5 75
Age at enrollment days, mean (SD)a 16.3 (10.4) 7.9 (4.7)
Death 0 1
Necrotizing enterocolitis 0 0
Total days of antibiotics (mean, SD) 34 (42) 56 (69)
Total days NPO, mean (SD) 15 (16) 17 (12)
Day of surgery (mean, SD) 15 (13) 13 (12)
Day of first enteral feedingb 14 (12) 7 (5)
Day of full enteral feedingb 21 (12) 39 (40)
Total days hospitalized, mean (SD) 53 (43) 80 (86)
ap=0.056 (t test).
b
two infants in the placebo group were not fed enterally during the study period.
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Table 2
Sample size calculations based on potentially beneficial observed changes in the first study week (all CHD 
patients with plasma and blood samples for baseline and week 1).
Probiotic mean change (SD) n=5 Placebo mean change (SD) n=4 Sample size estimate (per group)
IL6 −4.94 (20.2) 25.8 (56.9) 41
IL8 −10.2 (17.2) 1.94 (15.7) 21
IL10 446 (1010) 86.0 (179) 86
TNFα −2.42 (9.22) 4.00 (9.09) 43
Total bifidobacteria 4.0×109 (5.3×109) 5.5×106 (1.0×107) 19
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